AI Article Synopsis
- Polymorphisms in GST enzymes can affect cancer risk and the effectiveness of chemotherapy.
- A new PCR-based high-throughput genotyping assay has been developed that is cost-effective and reliable for large clinical trials.
- The study shows a strong correlation between certain GST gene variants and an increased risk of specific cancers like acute lymphoblastic leukemia and osteosarcoma.
Article Abstract
Polymorphisms of glutathione S-transferase (GST) enzymes have been correlated with altered risk of several cancers, as well as altered response and toxicity from cancer chemotherapy. We report a low cost, highly reproducible and specific PCR-based high-throughput assay for genotyping different GSTs designed for use in large clinical trials. In comparison to an alternative genotyping method (single nucleotide extension), the sensitivity and specificity of the high throughput assay was shown to be 92 and 97%, respectively, depending on the source of genomic DNA. Using the high-throughput assay, we demonstrate by multivariate analysis an increased risk of acute lymphoblastic leukemia, glial brain tumors, and osteosarcoma for patients carrying nonnull alleles of GSTM1 and/or GSTT1.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1158/1055-9965.epi-03-0178 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!